Silicon Valley and Wall Street are pouring billions into AI drug discovery in a high-stakes bet to “solve” disease.

Regulatory authorities emphasize integrated control strategies, but CAR-T specification setting requires balancing data rigor with regulatory flexibility.

Inside Realme’s labs, where a 10,001mAh battery is pushed through extreme drops, heat, and stress tests to ensure safety.| Technology News ...

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

Following the death by suicide of 42-year-old Kozhikode native Deepak U, who was accused via a video of sexually harassing a ...

German study proves automated sorting can recover nearly half of hospital plastic waste for recycling into new products ...

To this day, animal testing remains one of the most controversial issues in animal rights. Activists have been fighting ...

Pakistan, Jan. 24 -- The selection trials for the Lahore Division Women's Weightlifting team were successfully held at the ...

Jolene Latimer Her emotions could be felt through the screen. Christina Black had just carried an underdog run to the brink ...

In A Nutshell Personalized AI “health agents,” virtual drug trials, and automated compliance tools could quietly speed up ...

Effective procurement is not merely about finding the lowest-cost materials; it requires a clear communication channel ...

MANILA, Philippines — The possibility of two impeachment complaints against the country’s top two leaders signals political ...